Oncolytic peptide NF27 effectively inhibits tumor growth and eradicates tumors in multiple cancer types

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Oncolytic peptides offer therapeutic potential for cancer by selectively killing cancer cells.
• Few oncolytic peptides have reached clinical trials due to limitations in potency, safety, and understanding of structure-activity relationships (SAR).

Purpose of the Study:

• To design and evaluate novel oncolytic peptides based on existing structures.
• To elucidate the structure-activity relationship (SAR) of oncolytic peptides.
• To identify potent and safe oncolytic peptide candidates for cancer therapy.

Main Methods:

• Design and synthesis of a series of oncolytic peptides derived from the CKS1 peptide.
• In vitro evaluation of peptide cytotoxicity against various cancer cell lines and healthy cells.
• Assessment of hemolytic activity.
• In vivo studies using murine tumor models to evaluate anti-tumor efficacy and safety.
• Analysis of immunogenic cell death induction and immune cell infiltration.

Main Results:

• Identification of NF27 as a highly potent oncolytic peptide with broad-spectrum cytotoxicity against multiple cancer types.
• NF27 demonstrated minimal toxicity to healthy cells and low hemolytic activity.
• Tumor cell death induced by NF27 was immunogenic, promoting immune cell infiltration into tumors.
• NF27 significantly suppressed tumor growth in murine models, achieving complete tumor eradication in some cases with no observed side effects.

Conclusions:

• NF27 is a promising lead candidate for developing novel oncolytic peptide cancer therapies.
• The identified SAR provides valuable insights for designing future oncolytic peptides.
• NF27's potent anti-tumor activity, safety profile, and immunogenic properties make it a strong candidate for further clinical development.